Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan

Japanese Journal of Clinical Oncology

Volumn 42, Issue 12, 2012, Pages 1146-1151

  Bando, Hideaki ^a   Yoshino, Takayuki ^a   Yuki, Satoshi ^b   Shinozaki, Eiji ^c   Nishina, Tomohiro ^d   Kadowaki, Shigenori ^e   Yamazaki, Kentaro ^f   Kajiura, Shinya ^g   Tsuchihara, Katsuya ^a   Fujii, Satoshi ^a   Yamanaka, Takeharu ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cetuximab; Epidermal growth factor; Human; KRAS protein; Point mutation

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; COLORECTAL CANCER; DISEASE CONTROL; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84870466204     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys160     Document Type: Article

References (15)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
3. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
4. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
6. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28: 4706-13.
7. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60: 6750-6.
8. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. J Am Med Assoc 2010;304:1812-20.
9. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
11. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45.
12. Ogasawara N, Bando H, Kawamoto Y, et al. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffinembedded samples of colorectal cancers. Jpn J Clin Oncol 2010;41:52-6.
13. Bando H, Tsuchihara K, Yoshino T, et al. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-scorpion method and direct sequencing. Jpn J Clin Oncol 2011;41:239-44.
14. Fukushima Y, Yanaka S, Murakami K, et al. [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer]. Gan To Kagaku Ryoho 2011;38:1825-35 (in Japanese).
15. Bando H, Yoshino T, Tsuchihara K, et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011;105:403-6.